Status:
UNKNOWN
Nutritional Support During Antiviral Therapy for Hepatitis C
Lead Sponsor:
UMC Utrecht
Conditions:
Hepatitis C
Weight Loss
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Standard antiviral treatment consists of weekly injections with Peginterferon-α in combination with ribavirin. This treatment may lead to significant weight loss (7% within 24 weeks on average), with ...
Detailed Description
Standard antiviral treatment consists of weekly injections with Peginterferon-α in combination with ribavirin. This therapy, however, leads to weight loss of approximately 7% in the first 24 weeks of ...
Eligibility Criteria
Inclusion
- Diagnosis of hepatitis C
- Indication for antiviral therapy
- Age \> 18 years
- Good understanding of Dutch or English language
- Informed consent
Exclusion
- Co-infection with hepatitis B and/or HIV
- Significant non hepatic diseases
- Significant previous surgery of the gastro-intestinal tract
- Hepatocellular carcinoma or other current malignant disease
- BMI \< 20
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2010
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00841243
Start Date
March 1 2009
End Date
August 1 2010
Last Update
February 11 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UMC
Utrecht, Netherlands, 3509GA